ZA977510B - Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides. - Google Patents

Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides.

Info

Publication number
ZA977510B
ZA977510B ZA9707510A ZA977510A ZA977510B ZA 977510 B ZA977510 B ZA 977510B ZA 9707510 A ZA9707510 A ZA 9707510A ZA 977510 A ZA977510 A ZA 977510A ZA 977510 B ZA977510 B ZA 977510B
Authority
ZA
South Africa
Prior art keywords
betacyclohexyl
ethylglycyl
pseudopeptides
butanoyl
aspartyl
Prior art date
Application number
ZA9707510A
Other languages
English (en)
Inventor
Zofia J Chrzan
James J Mencel
David Toledo-Velasquez
Vincent Windisch
Rick G Woodward
Diane C Salazar
Narasimha M Vemuri
Anthony J Gardetto
Matthew R Powers
Gregory G Kubiak
Robert C Liu
Benoit J Vanasse
James P Sherbine
Walter Rodriguez
Adam W Sledeski
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of ZA977510B publication Critical patent/ZA977510B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ZA9707510A 1996-08-21 1997-08-21 Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides. ZA977510B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2428496P 1996-08-21 1996-08-21

Publications (1)

Publication Number Publication Date
ZA977510B true ZA977510B (en) 1998-05-21

Family

ID=21819807

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9707510A ZA977510B (en) 1996-08-21 1997-08-21 Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides.

Country Status (20)

Country Link
US (2) US6153588A (no)
EP (1) EP0923553B1 (no)
JP (1) JP4008499B2 (no)
KR (1) KR20000068229A (no)
CN (2) CN1491942A (no)
AP (1) AP9901462A0 (no)
AT (1) ATE390438T1 (no)
AU (1) AU733591B2 (no)
BG (1) BG63538B1 (no)
BR (1) BR9711340A (no)
CA (1) CA2263647C (no)
DE (1) DE69738601T2 (no)
EA (1) EA001362B1 (no)
IL (1) IL128561A0 (no)
NO (1) NO990721L (no)
OA (1) OA10979A (no)
PL (1) PL331772A1 (no)
SK (1) SK21999A3 (no)
WO (1) WO1998007696A1 (no)
ZA (1) ZA977510B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9711340A (pt) * 1996-08-21 1999-08-17 Rhone Poulenc Rorer Pharma Composto composi-Æo farmac-utica e processo para preparar um composto
WO1999019294A1 (en) * 1997-05-14 1999-04-22 Aventis Pharmaceuticals Products Inc. Legal/Patents Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
CA2306823A1 (en) * 1997-10-10 1999-04-22 Aventis Pharmaceuticals Products Inc. Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides
WO2000040601A1 (en) * 1998-12-30 2000-07-13 Aventis Pharmaceuticals Products Inc. Process for preparing a stable non-hygroscopic crystalline n-[n-[n- piperdin- 4-yl)butanoyl)- n.ethylglycyl]- (l)-aspartyl] -ss-cyclohexylalanine amide
US20050238834A1 (en) * 2004-04-21 2005-10-27 Eastman Kodak Company High modulus label with compliant carrier sheet
WO2007024501A2 (en) 2005-08-25 2007-03-01 Medtronic Vascular, Inc. Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) * 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US9704557B2 (en) * 2013-09-25 2017-07-11 Qualcomm Incorporated Method and apparatus for storing retention time profile information based on retention time and temperature
CA3009065C (en) 2015-12-21 2022-01-25 Texas Tech University System System and method for solution phase gap peptide synthesis
WO2019217116A1 (en) * 2018-05-06 2019-11-14 Gap Peptides Llc Method for solution-phase peptide synthesis
WO2020159837A1 (en) 2019-02-01 2020-08-06 Gap Peptides Llc Synthesis strategy for gap protecting group
US12024537B2 (en) 2018-05-31 2024-07-02 Sederma Compositions and methods for chemical synthesis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
US5332726A (en) * 1989-09-29 1994-07-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic peptides and pseudopeptides
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
US5264420A (en) 1990-09-27 1993-11-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5218138A (en) 1992-09-02 1993-06-08 Rhone-Poulenc Rorer Pharmaceuticals Inc. Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2166075A1 (en) * 1993-06-30 1995-01-12 Yoshiharu Ikeda Novel dipiperidine derivative
US5780590A (en) * 1993-10-15 1998-07-14 Rhone-Poulenc Rorer Pharmaceuticals Inc. Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
JP3032297B2 (ja) * 1993-10-15 2000-04-10 ローヌ‐プーラン ローラー ファーマシューティカルズ インコーポレイテッド 抗血栓性アザシクロアルキルアルカノイルペプチド及びプソイドペプチド
US5707994A (en) * 1993-10-19 1998-01-13 Sumitomo Pharmaceuticals Company, Limited 2,3-diaminopropionic acid derivative
BR9711340A (pt) * 1996-08-21 1999-08-17 Rhone Poulenc Rorer Pharma Composto composi-Æo farmac-utica e processo para preparar um composto
CA2306823A1 (en) * 1997-10-10 1999-04-22 Aventis Pharmaceuticals Products Inc. Process for the preparation of azacycloalkylalkanoyl pseudotetrapeptides

Also Published As

Publication number Publication date
EP0923553A1 (en) 1999-06-23
IL128561A0 (en) 2000-01-31
OA10979A (en) 2001-11-01
EP0923553B1 (en) 2008-03-26
JP2000517305A (ja) 2000-12-26
EA001362B1 (ru) 2001-02-26
ATE390438T1 (de) 2008-04-15
AP9901462A0 (en) 1999-03-31
DE69738601D1 (de) 2008-05-08
US6753409B1 (en) 2004-06-22
WO1998007696A1 (en) 1998-02-26
NO990721L (no) 1999-04-20
KR20000068229A (ko) 2000-11-25
JP4008499B2 (ja) 2007-11-14
CN1231659A (zh) 1999-10-13
PL331772A1 (en) 1999-08-02
DE69738601T2 (de) 2009-04-30
SK21999A3 (en) 2000-02-14
US6153588A (en) 2000-11-28
NO990721D0 (no) 1999-02-16
EP0923553A4 (en) 1999-12-08
AU4156397A (en) 1998-03-06
BG103225A (en) 2000-01-31
CA2263647C (en) 2011-02-15
BR9711340A (pt) 1999-08-17
CA2263647A1 (en) 1998-02-26
AU733591B2 (en) 2001-05-17
CN1491942A (zh) 2004-04-28
BG63538B1 (bg) 2002-04-30
EA199900217A1 (ru) 1999-08-26

Similar Documents

Publication Publication Date Title
ZA977510B (en) Stable non-hygroscopic crystalline form of N-[N-[N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl]aspartyl]-L-Betacyclohexyl alanine amide, intermediates thereof, and preparation thereof and of antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides.
PL334773A1 (en) Endothelin antagonists: n-[[2'-[[4,5-dimethyl-3-isoxazolyl)amino]sulphonyl]-4-(oxazoyl)[1,1'diphenyl]-ilyl-2]methyl]-n,3,3-trimethylabutane amide and n-(4,5-dimethyl-3-isoxazoyl)-2'-[3,3-dimethyl-2-oxo-1-pyrollydinyl)methyl]-4.-(2-oxazolyl)[1,1'-diphenyl]-2-sulphonamide and their salts
IL205233A0 (en) A polypeptide comprising the amino acid sequence of osteoprotegerin from residues 22 to 401 inclusive, or a fragment or trunaction thereof
WO2001090138A3 (en) SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING OXAZOLIDINONE DERIVATIVES
SG44989A1 (en) Crystalline hydrochloride of (R)-(-)-2-{N-[4-(1,1-dioxid-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl}-chroman
PL334184A1 (en) Fungicidal compositions based on methyl n-(phenylacetyl)-n-(2,6-xylyl) alaninate
BR9806060B1 (pt) composto n-[(aminoiminometil ou aminometil) fenil] propil amida, e, composição farmacêutica.
DK0889692T3 (da) Ny anvendelse af N-(phosphonomethyl)glycin og derivater deraf
NZ501346A (en) Valinyl aromatic beta amino acid dipeptide compounds having fungicidal activity and their agronomic use
DK0906094T3 (da) Substituerede N-[(aminoiminomethyl- eller aminomethyl)phenyl]propylamider
HUP0003847A3 (en) Basic salts of n-[n-(3,3-dimethylbutyl)-l-alpha-aspartyl]-l-phenylalanine 1-methyl ester
GR3031637T3 (en) Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
NO20001271D0 (no) Søtningssalter av N-[N-(3,3-dimetylbutyl)-L-<alfa>-aspartyl]- L-fenylalanin-1-metylester
BG103197A (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptiees
HUP0003573A3 (en) Acid salts of n-[n-(3,3-dimethylbutyl)-l-alpha-aspartyl]-l-phenylalanine 1-methyl ester
PL339190A1 (en) Complex compounds of metals with n-[n-(3,3-dimethylbutyl)-l-alpha-aspartil]-l-phenylamine 1-methyl ester
ZA976305B (en) Liquid phase peptide syntheses of KL-4 pulmonary surfactant protein
AU1936499A (en) Use of n-{n-(3,3-dimethylbutyl)-l-alpha-aspartyl}-l-phenylalanine 1-methyl esterin dairy and dairy analogue products
HUP0202516A3 (en) Methods for crystallization of n-(1-(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine n-carboxyanhydride
WO2000052019A3 (en) Crystallization products of neotame and methods for producing same
ZA958230B (en) Compositions containing a P53 derived from protein or peptide an adjuvant and interleukin-12 and uses thereof
AU3735095A (en) Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
AU4626796A (en) Novel sweeteners derived from 3,4-disubstituted alpha-benzeneamide n-(4-cyanophenylcarbamoyl or 2-cyanopyrid-5-ylcarbamoyl)-l-aspartic or l-glutamic acids
PL339360A1 (en) Method of crystallising n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanyl-l-proline maleate
FR2777279B1 (fr) Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide